St. Louis-based venture capital firm Cultivation Capital has invested in eight companies with its life sciences fund and should finish 2014 with around 10 portfolio companies, according to general partner Bill Schmidt. Cultivation Capital, which started out as a tech fund, added the life sciences fund last year and plans to spend $30 million over five years, with investments of between $250,000 and $1.25 million per company.
The fund’s eight portfolio companies span from research firms to biotechnology companies developing diagnostics and treatments for diseases such as cancer, stroke and glaucoma.
Schmidt says the fund will invest in 15 to 17 companies in all.
Some of the companies on Cultivation Capital’s life science portfolio include: Immunophotonics, Molecular Sensing, Adarza BioSystems, Cardialen, Euclises, Mobius Therapeutics, Pulse Therapeutics, Galera Therapeutics.